Published in World J Gastroenterol on February 28, 2015
Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol (2015) 0.76
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers Ther (2015) 0.75
SEED: the six excesses (Liu Yin) evaluation and diagnosis scale. Chin Med (2015) 0.75
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol (2017) 0.75
Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget (2017) 0.75
Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians. Pituitary (2017) 0.75
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med (1998) 5.89
Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med (2001) 5.29
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas (2010) 5.01
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med (1992) 4.33
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol (2008) 2.97
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol (2006) 2.80
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med (1980) 2.72
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.03
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res (2009) 2.00
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas (2010) 1.90
Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer (1993) 1.77
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 1.61
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol (2011) 1.51
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer (1996) 1.18
Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res (2008) 1.16
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol (2006) 1.11
Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas (2009) 1.01
A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control (2011) 1.00
Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther (2000) 0.94
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas (2013) 0.93
Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg (1993) 0.87
Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin. Br J Cancer (1999) 0.82